Generic Name:
Lasmiditan
Trade Name:
Reyvow
Company:
Eli Lilly
Notes:

On October 11, FDA approved lasmiditan tablets for acute (active but short-term) treatment of migraine with or without aura in adults. The drug is not indicated for preventive treatment of migraine.

Lasmiditan's effectiveness for acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials that included 3,177 adult patients with a history of migraine with and without aura. In both studies, the percentages of patients whose pain resolved and whose most bothersome migraine symptom (nausea, light sensitivity, or sound sensitivity) resolved 2 hours after treatment were significantly greater among patients receiving lasmiditan at all doses compared with those receiving placebo. Although patients were allowed to take a rescue medication 2 hours after taking lasmiditan, opioids, barbiturates, triptans and ergots were not allowed within 24 hours of the study drug?s administration. Twenty-two percent of patients were taking a preventive medication for migraine.

There is a risk of driving impairment while taking lasmiditan. Patients are advised not to drive or operate machinery for at least 8 hours after taking the medication, even if they feel well enough to do so. Patients who cannot follow this advice are advised not to take the drug. Lasmiditan causes central nervous system (CNS) depression, including dizziness and sedation. It should be used with caution if taken in combination with alcohol or other CNS depressants.

Common adverse effects are dizziness, fatigue, paresthesia, and sedation.

Medication Monitor Categories:
New Drug Approvals